NetworkNewsBreaks

TuesdayMar 21, 2017 1:24 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 21, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PULM 25.90% – News: Receives key patent from European Union HTBX 9.68% – News: Releases latest results from phase 2 trial of HS-110 in combination with nivolumab SPYR 9.09% – News: Issues shareholder update SPDL 7.76% – News: Enters digital marketing partnership with Mach One Media Group CATS 6.84% – News: Expands its OnTrak™-C coverage to Texas with leading insurance provider LOTE 5.97% – News: Appoints new CEO, plans first acquisition OWCP 5.38% –…

Continue Reading

TuesdayMar 21, 2017 1:10 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Obtains Patent for Use of CLR 124 in PET Imaging

Cellectar Biosciences (NASDAQ: CLRB) this morning said the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the cancer imaging agent that utilizes the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The newly issued patent, titled “Phospholipid Ether Analogs as Agents for Detecting and Locating Cancer and Methods Thereof,” provides intellectual property protection through March 2, 2025. The patent outlines the use of CLR 124 in PET imaging to detect radiation-insensitive or chemotherapy-insensitive cancers and cancer metastases. Additionally, the patent provides coverage for the use of CLR 124 in identifying the location…

Continue Reading

TuesdayMar 21, 2017 1:04 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Reiterated with “Buy” Rating, $10 PT at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $10 on shares of Celldex Therapeutics’ (NASDAQ: CLDX) stock. The news follows the company’s report of business and financial highlights for the fourth quarter and year-ended December 31, 2016. The company reported total revenue of $1.9 million in the fourth quarter of 2016, and full-year revenue of $6.8 million, compared to $1.8 million and $5.5 million for the comparable periods in 2015. The company credited the increase in revenue to its clinical trial collaboration with Bristol-Myers Squibb. The company also provided an update on its pipeline, including the increase…

Continue Reading

TuesdayMar 21, 2017 12:53 pm

NetworkNewsBreaks – Caladrius Biosciences, Inc. (NASDAQ: CLBS) Receives “Buy” Rating, $15 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $15 on shares of Caladrius Biosciences’ (NASDAQ: CLBS) stock. The company recently reported financial results for the three and 12 months ended December 31, 2016. The company full year revenues of $35.3 million, an increase of 57% compared with $22.5 million for 2015. Caladrius also reported cash at year-end of $14.7 million. Additionally, the company recently announced the sale of the remaining 80.1% interest in its PCT LLC subsidiary to Hitachi Chemical for $75 million in cash with an additional $5 million payable upon reaching an undisclosed revenue milestone…

Continue Reading

TuesdayMar 21, 2017 12:40 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating, $3 PT on Achaogen, Inc. (NASDAQ: AKAO)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $29 on shares of Achaogen’s (NASDAQ: AKAO) stock. The biopharmaceutical company recently reported financial results for the fourth quarter and year ended December 31, 2016, posting total Q4 contract revenue of $10.7 million, which was less than expected. Analysts cited the company’s uneventful fourth quarter in the report, but mentioned that milestones and catalysts are more important in evaluating clinical-stage development companies. Achaogen also recently released an update on its lead product candidate, Plazomicin, which has shown positive results in two phase 3 clinical trials. The company plans to…

Continue Reading

TuesdayMar 21, 2017 11:37 am

NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 Demonstrates Considerable Potential as HIV Treatment

Though considerable advances have been made in the prevention and treatment of HIV/AIDS, more than 1.2 million people in the U.S. are still affected by the disease. CytoDyn Inc.’s (OTCQB: CYDY) PRO 140 candidate is considered one of the most advanced experimental monoclonal antibodies for HIV treatment, and it has been used in more than 140 HIV-positive patients in placebo-controlled and open label FDA-approved clinical trials. “The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and has been designated a ‘fast track’ product candidate…

Continue Reading

TuesdayMar 21, 2017 10:37 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Teams with Planet Payment to Offer Multi-Currency Pricing

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE) this morning announced that its Unified Payments subsidiary has entered into a strategic partnership with Planet Payment, Inc. (NASDAQ: PLPM), a leading provider of international and multi-currency payment processing services. Through this agreement, Unified Payments will offer Planet Payment’s Multi-Currency Pricing to its portfolio of online merchants, enabling them to more effectively expand into foreign markets by displaying pricing and accepting payments in a variety of local currencies. “We are excited to form this partnership with Planet Payment to bring our online merchants the ability to price in multiple currencies and…

Continue Reading

TuesdayMar 21, 2017 9:58 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Files Provisional Patent for Treatment of Eating Disorders Using Cannabis Extracts

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its filing of a provisional patent for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. Should this filing result in the issuance of a patent, IGC intends to develop its IGC-506 candidate for both human and veterinary use. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector,” Ram Mukunda, chief executive officer…

Continue Reading

MondayMar 20, 2017 1:34 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 20, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ATLT 20.00% – News: Expects significant gains for Q3 ended March 31, 2017 NMUS 18.37% – News: Signs development agreement with Nanomerics Ltd. for ocular formulation NB1111 AKDS 15.79% – News: Inks LOI to acquire SolBright Renewable Energy GLBR 13.79% – News: Posts Q4 2016 results COYN 8.36% – News:  COPsync Network continues to grow ALQA 8.10% – News: Peer-reviewed study on MIST Therapy for deep tissue pressure injuries published in Wound Repair &…

Continue Reading

MondayMar 20, 2017 12:15 pm

NetworkNewsBreaks – BioLineRx (NASDAQ: BLRX) Reports Interim Results on Phase 2 Study of BL-8040 in Stem Cell Mobilization

BioLineRx (NASDAQ: BLRX) this morning reported partial results data from its open-label phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood. Interim results from the initial cohort of donor and recipient pairs show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. So far, all transplant recipients have experienced a successful neutrophil engraftment. Recipients will continue to be…

Continue Reading